Department of Obstetrics and Gynecology, Rambam Health Care Campus, Technion Faculty of Medicine, 6 Ha'Aliya Street, 31096 Haifa, Israel.
Int Urol Nephrol. 2012 Apr;44(2):425-9. doi: 10.1007/s11255-011-0059-y. Epub 2011 Oct 13.
To evaluate the test-retest reliability of a device that measures urinary sensation during cystometry, and to use that device to determine whether treatment of overactive bladder syndrome (OAB) with solifenacin is associated with a change in urinary sensation.
Overall 15 women were recruited for this study, ten women with OAB and urodynamically demonstrated detrusor overactivity and five controls without OAB underwent filling cystometry twice with contemporaneous, continuous recording of urinary sensation. Women with OAB received solifenacin 10 mg daily during the weeks between testing. We compared the areas under the initial and repeat sensation-volume curves.
While taking solifenacin, the maximum cystometric capacity increased from 329 ± 168 ml to 464 ± 123 ml (P < 0.002), and the area under the bladder volume-sensation curve decreased (P < 0.0001). Untreated controls did not exhibit these changes.
We present psychometric data demonstrating improved bladder sensation during the treatment of OAB with solifenacin. If clinical correlations are confirmed by future study, such urinary sensation measures may prove useful as assessment, treatment predictor, or outcome measures in OAB research and/or clinical care.
评估一种在膀胱测压期间测量尿感的设备的重测信度，并使用该设备来确定索利那新治疗膀胱过度活动症（OAB）是否与尿感的变化有关。
本研究共招募了 15 名女性，其中 10 名患有 OAB 且尿动力学检查显示逼尿肌过度活动，5 名对照者无 OAB，这两组女性均进行了两次充盈性膀胱测压，同时进行连续的尿感记录。在两次测压之间，OAB 女性接受索利那新 10mg 每日治疗。我们比较了初始和重复尿感-膀胱容量曲线下的面积。
服用索利那新后，最大膀胱容量从 329 ± 168ml 增加到 464 ± 123ml（P < 0.002），膀胱容量-尿感曲线下的面积减少（P < 0.0001）。未接受治疗的对照组没有出现这些变化。
我们提供了心理测量学数据，证明了在 OAB 用索利那新治疗期间膀胱感觉的改善。如果未来的研究证实了临床相关性，那么这种尿感测量方法可能会在 OAB 研究和/或临床护理中作为评估、治疗预测或结果测量指标证明是有用的。
